Laura Ridolfi MD PhD

Dirigente Medico, PhD, Unità di Immunoterapia c/o IRST-IRCCS, Meldola (FC).

[Waggoner Lab @LabWaggoner]

REVIEW @NatRevImmunol
The danger theory of immunity revisited
https://t.co/Yyp8tNLaCw

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC commentary: Immune checkpoint blockade: timing is everything https://t.co/AAEbwWXdJF @FASinicropeMD

[Arndt Vogel @ArndtVogel]

Bispecific antibodies: advancing precision oncology
@trendscancer
https://t.co/uhCNTzMKIO
👉Bispecific antibodies are on the rise with promising data
👏Excellent in depth review
@myESMO

[Trends in Immunology @TrendsImmuno]

The extracellular matrix in solid tumor immunotherapy https://t.co/ctji0FJUAO #immunology

[Nature Reviews Nephrology @NatRevNeph]

Mechanisms underlying sex differences in the production of type I interferon.

https://t.co/I8xKiLQMpG

[Jeffrey Molter @JeffreyLMolter]

Dr. Jeffrey S. Weber, deputy director ⁦@nyulangone⁩’s ⁦@Perlmutter_CC⁩ died today! He was the consummate melanoma physician scientist that advanced the field immensely. We will dearly miss him!!

[Vivek Subbiah, MD @VivekSubbiah]

🚨It's Friday and we have another FDA approval !
👉FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma
👉Afamitresgene autoleucel is also the first FDA-approved T cell receptor (TCR) gene therapy.
👉The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells are modified to express a TCR that targets MAGE-A4, an antigen (substance that normally triggers your immune system) expressed by cancer cells in synovial sarcoma. 👉The product is administered as a SINGLE intravenous dose.
👉Huge congrats to the trials team, patients and all their caregivers who made it happen👏.
HLA = human leukocyte antigen; SPEAR = Specific Peptide Enhanced Affinity Receptor; TCR = T-cell receptor @bvantine1 @DrBetofMDPhD @DavidHongMD @Adaptimmune @OncoAlert
https://t.co/q62iBhVDP0

[Waggoner Lab @LabWaggoner]

Tumor extracellular vesicles deliver neoantigens to sentinel node follicles activating germinal centers, epitope spreading and CD8 T infiltration, restricting immunotherapy-resistant squamous carcinoma @fepulab @hollern_daniel
https://t.co/TtjC3WVUs3

[Cell @CellCellPress]

In the latest issue! Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity https://t.co/Xslp9MaGXT

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Interested in cell therapies in oncology? A new landscape analysis from @CancerResearch Institute and @IQVIA_global discusses clinical research and real-world data on the use and implementation of this modality https://t.co/XxXAfrdVSg

[Immunity @ImmunityCP]

Online now: Progenitors of distinct lineages shape the diversity of mature type 2 conventional dendritic cells https://t.co/6KwSMjk3Vm

[Teresa Amaral, MD, PhD @TeresaSAmaral]

First OS data in the adjuvant setting in #melanoma
20% risk of death for pts with #melanoma treated with adjuvant dabra+trama but not statistically significant - practice change?
#skincancer #ASCO24 @myESMO

[Nature Rev Immunol @NatRevImmunol]

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations https://t.co/RxnRHPenWY

[Maria Kfoury @kfoury_maria]

Sex matters in immunotherapy !
Impact of sex on response to ICI & occurrence of some IRAE. Potential immunosuppressive impact of Androgens.

Could androgen dosing in clinics help identify patients at risk of IRAE / correlate to response?
#ESMOImmuno23 @champiatMD @prochigneux

[ESMO - Eur. Oncology @myESMO]

#ESMOImmuno23: Receiving the ESMO Immuno-Oncology Award 2023, Steven A. Rosenberg discusses the challenges in cell-based immunotherapies, as well as the opportunities and the keys to further progress in this field.
👉https://t.co/F5ft8bmBSr
#ESMODailyReporter

[Laura Ridolfi MD PhD @Lauraridolfi3]

Exiting #ESMOImmuno23 with new ideas new contacts to improve our cell therapies for solid tumors

[Omniscope @OmniscopeAI]

Looking forward to present our results at the Thursday poster session. Look out, Geneva! Here we come!

To speak to our team at ESMO Immuno Oncology 2023:
🤝 https://t.co/N7RN2MSyqf

#ESMOImmuno23 #ScienceIsWeAll

[ESMO - Eur. Oncology @myESMO]

#ESMOImmuno23: LBA authors & titles online, plus all accepted abstracts 🙌 Head to the programme & prepare for this global event. Like what you see & not yet registered? You can still do so here 👉 https://t.co/WS9igIHoQE
#ImmunoOncology @VriesElisabeth @DrJNaidoo @amanda_psyrri

[Max Mamonkin @MaxMamonkin]

T-cell malignancies can arise after other therapies, including checkpoint blockade (<0.1% cases). Need to see if CART-related malignancies are directly attributed to viral transduction. https://t.co/P0dIBARQRH

[Frontiers - Immunology @FrontImmunol]

New Research: Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges: Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target antigen through an… https://t.co/VNy49Gd4HU #immunology